Elimination of factor VIII‐specific B cells by immunotoxins composed of a single factor VIII domain fused to Pseudomonas exotoxin A

Essentials There is still a need for novel therapeutic approaches for hemophilia A patients with inhibitors. A factor VIII domain was used as the targeting moiety for elimination of FVIII‐specific B cells. The immunodominant C2 domain was fused to exotoxin A from Pseudomonas aeruginosa (hC2‐ETA). Murine C2 domain‐specific B cells were selectively and efficiently eliminated by hC2‐ETA ex vivo.

• Publication year

  2018

• Venue

  Journal of Thrombosis and Haemostasis

• Publication date

  2018-10-08

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1111/jth.14273PMID 30152083
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Frequency and epitope specificity of anti-factor VIII C1 domain antibodies in acquired and congenital hemophilia A.

  2017cited by this paper
• Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens

  2017cited by this paper
• The C1 and C2 domains of blood coagulation factor VIII mediate its endocytosis by dendritic cells

  2017cited by this paper
• Neutralisation of factor VIII inhibitors by anti-idiotypes isolated from phage-displayed libraries

  2016cited by this paper
• High-affinity, noninhibitory pathogenic C1 domain antibodies are present in patients with hemophilia A and inhibitors.

  2016cited by this paper
• Antibody-drug conjugates—an emerging class of cancer treatment

  2016cited by this paper
• A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects.

  2016cited by this paper
• Immunogenicity of therapeutic recombinant immunotoxins

  2016cited by this paper
• Tolerogenic nanoparticles to induce immunologic tolerance: Prevention and reversal of FVIII inhibitor formation.

  2016cited by this paper
• Novel fusion proteins for the antigen-specific staining and elimination of B cell receptor-positive cell populations demonstrated by a tetanus toxoid fragment C (TTC) model antigen

  2016cited by this paper
• Antibody-Drug Conjugates for Tumor Targeting-Novel Conjugation Chemistries and the Promise of non-IgG Binding Proteins.

  2015cited by this paper
• Expanding the ortholog approach for hemophilia treatment complicated by factor VIII inhibitors

  2015cited by this paper
• Regulation of immune responses to protein therapeutics by transplacental induction of T cell tolerance

  2015cited by this paper
• Evaluation of Enhanced in Vitro Plasma Stability of a Novel Long Acting Recombinant FVIIIFc-VWF-XTEN Fusion Protein

  2015cited by this paper
• Rituximab for treatment of inhibitors in haemophilia A

  2014cited by this paper
• Decreasing the Humoral Response to Factor VIII By Targeted Deletion of Factor VIII - Specific B Cells

  2014cited by this paper
• B-Cell Epitopes Within The A2 and C2 Domains Of Coagulant Factor VIII Refined By Orthologous Protein Antigenicity

  2013cited by this paper
• Selection and characterisation of FVIII-specific single chain variable fragments

  2013cited by this paper
• The principal results of the International Immune Tolerance Study: a randomized dose comparison.

  2012cited by this paper
• Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective

  2012cited by this paper
• Modern haemophilia care.

  2012cited by this paper
• Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2).

  2012cited by this paper
• In vivo efficacy of the recombinant anti‐CD64 immunotoxin H22(scFv)‐ETA′ in a human acute myeloid leukemia xenograft tumor model

  2011cited by this paper
• Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma‐derived or recombinant factor VIII concentrates: a systematic review

  2010cited by this paper
• Modulation of factor VIII‐specific memory B cells

  2010cited by this paper
• B Cell Antigen Receptor Endocytosis and Antigen Presentation to T Cells Require Vav and Dynamin

  2009cited by this paper
• A role for thrombin in the initiation of the immune response to therapeutic factor VIII.

  2009cited by this paper
• Memory B cells: Effectors of long‐lived immune responses

  2009cited by this paper
• Pseudomonas exotoxin A: from virulence factor to anti-cancer agent.

  2009cited by this paper
• Depletion of autoreactive B-lymphocytes by a recombinant myelin oligodendrocyte glycoprotein-based immunotoxin.

  2008cited by this paper
• Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation.

  2007cited by this paper
• The humoral response to human factor VIII in hemophilia A mice

  2007cited by this paper
• Managing acute bleeds in the patient with haemophilia and inhibitors: options, efficacy and safety

  2005cited by this paper
• High-dose factor VIII inhibits factor VIII-specific memory B cells in hemophilia A with factor VIII inhibitors.

  2005cited by this paper
• Managing acute bleeds in the patient with haemophilia and inhibitors: options, efficacy and safety.

  2005cited by this paper
• Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins.

  2005cited by this paper
• Inhibitors in hemophilia A: mechanisms of inhibition, management and perspectives

  2004cited by this paper
• Immunodominant T-cell epitopes in the factor VIII C2 domain are located within an inhibitory antibody binding site

  2004cited by this paper
• Preventing restimulation of memory B cells in hemophilia A: a potential new strategy for the treatment of antibody-dependent immune disorders.

  2004cited by this paper
• Factor VIII alloantibodies in hemophilia

  2004cited by this paper
• Epitope specificity of anti-FVIII antibodies during immune tolerance therapy with factor VIII preparation containing von Willebrand factor.

  2002cited by this paper
• Long-term Persistence of Anti-factor VIII Antibody-secreting Cells in Hemophilic Mice after Treatment with Human Factor VIII

  2002cited by this paper
• Phospholipid-Binding Domain of Factor VIII Is Involved in Endothelial Cell–Mediated Activation of Factor X by Factor IXa

  2002cited by this paper
• Structure of a factor VIII C2 domain-immunoglobulin G4kappa Fab complex: identification of an inhibitory antibody epitope on the surface of factor VIII.

  2001cited by this paper
• Hemophilic factor VIII C1- and C2-domain missense mutations and their modeling to the 1.5-angstrom human C2-domain crystal structure.

  2000cited by this paper
• Ki-4(scFv)-ETA', a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice.

  2000cited by this paper
• Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo

  2000cited by this paper
• Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules.

  2000cited by this paper
• Ki-4(scFv)–ETA′, a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice

  2000cited by this paper
• Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor.

  1998cited by this paper
• The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study Groups.

  1997cited by this paper
• Targeted therapy of Schwannoma cells in immunocompetent rats with an erbB2‐specific antibody‐toxin

  1997cited by this paper
• In vitro enzyme activation and folded stability of Pseudomonas aeruginosa exotoxin A and its C-terminal peptide.

  1996cited by this paper
• In vitro enzyme activation and folded stability of Pseudomonas aeruginosa exotoxin A and its C-terminal peptide.

  1996cited by this paper
• Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A

  1995cited by this paper
• Residues 484-508 Contain a Major Determinant of the Inhibitory Epitope in the A2 Domain of Human Factor VIII (*)

  1995cited by this paper
• Anaesthesia of animals for biomedical research.

  1993cited by this paper
• Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor.

  1992cited by this paper

• Blunting specific T-dependent antibody responses with engineered 'decoy' B cells.

  2024cites this paper
• Immunogenicity of Protein Pharmaceuticals.

  2019cites this paper